AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1688482 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg of sotalol administered twice daily
Number of subjects: 172
Study 1688482 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of propranolol administered 3 times daily
Number of subjects: 172
Study 1688482 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg of sotalol administered twice daily
Number of subjects: 172
Study 1688482 — intervention group
Group type: COMPARATOR
Intervention: 80 mg of propranolol administered 3 times daily
Number of subjects: 172
Study 371742 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and Thalazole
Number of subjects: 120
Study 371742 — intervention group
Group type: COMPARATOR
Intervention: Thalazole alone
Number of subjects: 120
Study 31736337 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Number of subjects: 2479
Study 31736337 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 2479
Study 30617697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunches served in CCs
Number of subjects: 61
Study 30617697 — intervention group
Group type: COMPARATOR
Intervention: Saskatchewan centres
Number of subjects: 61
Study 30617697 — intervention group
Group type: COMPARATOR
Intervention: French-speaking centres
Number of subjects: 61
Study 30617697 — intervention group
Group type: COMPARATOR
Intervention: Rural and urban centres
Number of subjects: 61
Study 26117466 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg loading dose (LD) of ticagrelor
Number of subjects: 60
Study 26117466 — intervention group
Group type: COMPARATOR
Intervention: 90 mg maintenance dose (MD) of ticagrelor
Number of subjects: 60
Study 23229236 — intervention group
Group type: COMPARATOR
Intervention: Anesthetic blockage of the auriculotemporal nerve with injections of 1 ml of bupivacaine 0.5% without vasoconstrictor for 8 weeks (group 1)
Number of subjects: 20
Study 23229236 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic blockage and physical therapy (massage and muscular stretching exercises) (group 2)
Number of subjects: 20
Study 21451030 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector average readout of direction signals accumulated over time
Number of subjects: 0
Study 21451030 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood readout of direction signals combined over space
Number of subjects: 0
Study 21451030 — intervention group
Group type: EXPERIMENTAL
Intervention: Population decoding model simulations
Number of subjects: 0
Study 19351633 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma apelin concentration post-AMI
Number of subjects: 100
Study 19351633 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma apelin concentration at 24 weeks post-AMI
Number of subjects: 100
Study 19351633 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of baseline apelin with norepinephrine
Number of subjects: 100
Study 19351633 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and norepinephrine correlation with adverse ventricular function
Number of subjects: 100
Study 19351633 — intervention group
Group type: COMPARATOR
Intervention: Control group (38 subjects with no cardiac history)
Number of subjects: 100
Study 16690431 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine (131I) metuximab injection (27.75 MBq/kg)
Number of subjects: 134
Study 15066459 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil citrate (VIAGRA)
Number of subjects: 20
Study 15066459 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐Bromo‐cGMP (20 microM; 60 minutes)
Number of subjects: 20
Study 15066459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11446841 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily
Number of subjects: 55
Study 11446841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9730139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pvu II +/+ genotype in low-HDL/high-TG children
Number of subjects: 308
Study 9730139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pvu II+ allele of the LPL gene
Number of subjects: 308
Study 9730139 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL(Arita) mutation
Number of subjects: 308
Study 9730139 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL Asn291Ser and Gly188Glu variants
Number of subjects: 308
Study 8014692 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin alone
Number of subjects: 16
Study 8014692 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin plus recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 16
Study 8014692 — intervention group
Group type: COMPARATOR
Intervention: Packed erythrocyte transfusions
Number of subjects: 16
Study 8014692 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin plus GM-CSF
Number of subjects: 16
Study 2567579 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 receptor antagonist, levocabastine
Number of subjects: 15
Study 2567579 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 receptor antagonist, ranitidine
Number of subjects: 15
Study 2567579 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 and/or H2 antagonists
Number of subjects: 15
Study 2567579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 5335457 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0
Study 5335457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31425283 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic coaching behavior during surgery
Number of subjects: 20
Study 31425283 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-identified goals
Number of subjects: 20
Study 31425283 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative analysis
Number of subjects: 20
Study 31425283 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching principles
Number of subjects: 20
Study 30695071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 30695071 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 27798730 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib treatment
Number of subjects: 0
Study 27798730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26295507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone cream
Number of subjects: 27
Study 26295507 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo cream
Number of subjects: 27
Study 26295507 — intervention group
Group type: COMPARATOR
Intervention: No cream application (Control)
Number of subjects: 27
Study 23613569 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 50/250 µg, twice daily
Number of subjects: 1543
Study 23613569 — intervention group
Group type: COMPARATOR
Intervention: SAL 50 µg, twice daily
Number of subjects: 1543
Study 22065897 — intervention group
Group type: EXPERIMENTAL
Intervention: GC501
Number of subjects: 283
Study 19380124 — intervention group
Group type: EXPERIMENTAL
Intervention: History-indicated cervical cerclage
Number of subjects: 247
Study 19380124 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-indicated cervical cerclage
Number of subjects: 247
Study 16501262 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based teaching on two of the four urologic topics
Number of subjects: 351
Study 16501262 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based teaching
Number of subjects: 351
Study 16501262 — intervention group
Group type: COMPARATOR
Intervention: No Web-based teaching
Number of subjects: 351
Study 15181058 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone therapy (CHT) - continuous conjugated equine estrogen/cyclical micronized progesterone for 3 months
Number of subjects: 15
Study 15181058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10886121 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 16
Study 10886121 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 22 mg
Number of subjects: 16
Study 10886121 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg + Yohimbine 22 mg
Number of subjects: 16
Study 10886121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11480052 — intervention group
Group type: EXPERIMENTAL
Intervention: Koukangning gargle (experimental group, 59 patients)
Number of subjects: 118
Study 11480052 — intervention group
Group type: COMPARATOR
Intervention: Dobell's solution (control group 1, 29 patients)
Number of subjects: 118
Study 11480052 — intervention group
Group type: COMPARATOR
Intervention: Koutai solution (control group 2, 30 patients)
Number of subjects: 118
Study 8513841 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose hamamelis PC-cream
Number of subjects: 24
Study 8513841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% cream
Number of subjects: 24
Study 8513841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamamelis cream (without PC)
Number of subjects: 24
Study 8513841 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile cream
Number of subjects: 24
Study 8513841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamamelis PC-cream
Number of subjects: 24
Study 8513841 — intervention group
Group type: COMPARATOR
Intervention: Untreated control area
Number of subjects: 24
Study 2948431 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 18
Study 2948431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 18
Study 2948431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting condition
Number of subjects: 18
Study 2948431 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study 31808686 — intervention group
Group type: EXPERIMENTAL
Intervention: MHBAs (35 mg/day)
Number of subjects: 60
Study 29629845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 29629845 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 28290272 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP beverage (333 mg SCP) daily for 6 weeks
Number of subjects: 41
Study 28290272 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (0 mg SCP)
Number of subjects: 41
Study 28290272 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP beverage (333 mg SCP)
Number of subjects: 41
Study 25504868 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 51
Study 23172972 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (weight lifting)
Number of subjects: 12
Study 23172972 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (running at 60% of Vo(2max))
Number of subjects: 12
Study 23172972 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 12
Study 21240015 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 75 mg · kg⁻¹ · day⁻¹ (high dose)
Number of subjects: 86
Study 21240015 — intervention group
Group type: COMPARATOR
Intervention: Calcium 45 mg · kg⁻¹ · day⁻¹ (low dose)
Number of subjects: 86
Study 18325386 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg orally twice daily
Number of subjects: 105
Study 18325386 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 105
Study 16443339 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fat tolerance test (OFTT) in menopausal women with MetS
Number of subjects: 33
Study 12900303 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 45
Study 12900303 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 45
Study 10096976 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass
Number of subjects: 156
Study 10096976 — intervention group
Group type: COMPARATOR
Intervention: Uncoated cardiopulmonary bypass
Number of subjects: 156
Study 8905004 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol inhaled via dry-powder (DP) capsule inhaler
Number of subjects: 12
Study 8905004 — intervention group
Group type: COMPARATOR
Intervention: Formoterol inhaled via pressurized metered-dose inhaler (pMDI)
Number of subjects: 12
Study 1910651 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly (intensive) neurodevelopmental therapy
Number of subjects: 29
Study 1910651 — intervention group
Group type: COMPARATOR
Intervention: Monthly (basic) neurodevelopmental therapy
Number of subjects: 29
Study 7082780 — intervention group
Group type: EXPERIMENTAL
Intervention: New enteric-coated phenylbutazone (100 mg and 200 mg)
Number of subjects: 8
Study 7082780 — intervention group
Group type: COMPARATOR
Intervention: Commercially available Butacote
Number of subjects: 8
Study 31861714 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar lordotic curve-controlled traction (L-LCCT)
Number of subjects: 40
Study 31861714 — intervention group
Group type: COMPARATOR
Intervention: Traditional traction (TT)
Number of subjects: 40
Study 29656145 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 SQ‐HDM
Number of subjects: 2138
Study 29656145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2138
Study 27812637 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg
Number of subjects: 20
Study 27812637 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 150 µg
Number of subjects: 20
Study 24262762 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg
Number of subjects: 12
Study 24262762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22582889 — intervention group
Group type: EXPERIMENTAL
Intervention: Training under a mentor for 2 hours
Number of subjects: 36
Study 22582889 — intervention group
Group type: COMPARATOR
Intervention: Training without a mentor for 2 hours
Number of subjects: 36
Study 20678621 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 1542
Study 20678621 — intervention group
Group type: COMPARATOR
Intervention: Open mesh repair (Lichtenstein group)
Number of subjects: 1542
Study 17377602 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 731
Study 17377602 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 731
Study 11052900 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve mobilization
Number of subjects: 21
Study 11052900 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal bone mobilization
Number of subjects: 21
Study 11052900 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 21
Study 11052900 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 21
Study 9444800 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg prolonged-release capsule per day
Number of subjects: 40
Study 9444800 — intervention group
Group type: COMPARATOR
Intervention: 50 mg enteric-coated tablet every 8 hours
Number of subjects: 40
Study 8154260 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dietary supplement of a mixture consisting of vitamins (A, B1, B2, B6, E) and trace elements (calcium, iron, manganese)
Number of subjects: 60
Study 8154260 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dietary supplement of purely vitamin C tablets
Number of subjects: 60
Study 8154260 — intervention group
Group type: COMPARATOR
Intervention: Control group (1/3 of subjects)
Number of subjects: 60
Study 2876233 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose frusemide
Number of subjects: 10
Study 2876233 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10
Study 29851760 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg vitamin D supplements
Number of subjects: 206
Study 29851760 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D supplements
Number of subjects: 206
Study 29851760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 μg)
Number of subjects: 206
Study 26099215 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 100 mg BID for the first 24 hours followed by 50 mg BID for the following 13 days
Number of subjects: 351
Study 26099215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 24101016 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Number of subjects: 27
Study 24101016 — intervention group
Group type: COMPARATOR
Intervention: Conventional open esophagectomy (OE)
Number of subjects: 27
Study 23952183 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemental health (TMH) intervention, average of 5.3 of 6.0 planned sessions completed.
Number of subjects: 223
Study 23952183 — intervention group
Group type: COMPARATOR
Intervention: Control group (TMH consultation), 96% completed a TMH consultation.
Number of subjects: 223
Study 23952183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups completed an average of 4.8 of the 5.0 assessments.
Number of subjects: 223
Study 19488796 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm fluoride dentifrice
Number of subjects: 72
Study 19488796 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 ppm fluoride dentifrice
Number of subjects: 72
Study 19488796 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 ppm fluoride dentifrice
Number of subjects: 72
Study 19488796 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm fluoride dentifrice
Number of subjects: 72
Study 19488796 — intervention group
Group type: COMPARATOR
Intervention: 250 ppm fluoride dentifrice
Number of subjects: 72
Study 18786088 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 40
Study 18786088 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 40
Study 16670161 — intervention group
Group type: EXPERIMENTAL
Intervention: T(4) dosage adjustment aiming for serum TSH concentration less than 2 mU/liter
Number of subjects: 56
Study 16670161 — intervention group
Group type: COMPARATOR
Intervention: T(4) dosage adjustment aiming for serum TSH concentration in the upper reference range
Number of subjects: 56
Study 12786770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine b.i.d. with nedocromil rescue
Number of subjects: 89
Study 12786770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine q.d. with nedocromil b.i.d.
Number of subjects: 89
Study 12786770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine rescue with nedocromil b.i.d.
Number of subjects: 89
Study 12786770 — intervention group
Group type: COMPARATOR
Intervention: All regimens
Number of subjects: 89
Study 12786770 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fexofenadine dosages with nedocromil b.i.d.
Number of subjects: 89
Study 11512311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) as part of immunosuppression therapy
Number of subjects: 367
Study 11512311 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine as part of immunosuppression therapy
Number of subjects: 367
Study 11512311 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stenting of posttransplant renal artery stenosis
Number of subjects: 367
Study 11512311 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound scanning
Number of subjects: 367
Study 11512311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 367
Study 8863274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% oral rinse
Number of subjects: 0
Study 8863274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% oral rinse
Number of subjects: 0
Study 8863274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% oral rinse
Number of subjects: 0
Study 8863274 — intervention group
Group type: COMPARATOR
Intervention: 10 mg peroral ketorolac capsule
Number of subjects: 0
Study 8863274 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% dentifrice
Number of subjects: 0
Study 8863274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% dentifrice
Number of subjects: 0
Study 1371550 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the prostate
Number of subjects: 33
Study 1371550 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy
Number of subjects: 33
Study 31264800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy for Children (MBCT-C)
Number of subjects: 24
Study 31264800 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 24
Study 30149341 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal PM2.5 exposure measured using low-cost personal monitors over one week (five weekdays and one weekend)
Number of subjects: 14
Study 30149341 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal PM2.5 exposure measured during weekdays and weekends
Number of subjects: 14
Study 30149341 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal PM2.5 exposure in relation to distance from roads
Number of subjects: 14
Study 30149341 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal PM2.5 exposure in relation to open space
Number of subjects: 14
Study 30149341 — intervention group
Group type: EXPERIMENTAL
Intervention: Community perception of air pollution exposure
Number of subjects: 14
Study 26541906 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming exercise
Number of subjects: 48
Study 26541906 — intervention group
Group type: COMPARATOR
Intervention: Cycling training
Number of subjects: 48
Study 24068549 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS)
Number of subjects: 68
Study 24068549 — intervention group
Group type: COMPARATOR
Intervention: Conventional pathway (control)
Number of subjects: 68
Study 22135277 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg p.o. q.d. for 5 days
Number of subjects: 1056
Study 22135277 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid 875/125 mg p.o. b.i.d. for 7 days
Number of subjects: 1056
Study 22135277 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 1056
Study 22135277 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 1056
Study 20568520 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-derived stem cells (MDSCs) therapy
Number of subjects: 0